Group 1 - The core viewpoint of the article highlights the transfer of shares of Mace Health (02415) from Merrill Lynch Far East Limited to China International Financial Hong Kong Securities, with a market value of HKD 88.21 million, representing 10.53% of the company [1] - Mace Health reported a mid-term revenue of RMB 125 million for 2025, reflecting a year-on-year growth of 13.2% [1] - The net profit for Mace Health reached RMB 13.239 million, showing a significant year-on-year increase of 5238.3% [1] Group 2 - The basic earnings per share for Mace Health were reported at 2.45 cents, with a proposed interim dividend of 1.1 Hong Kong cents per share [1] - The increase in total revenue is attributed to the recovery in the pharmaceutical industry and the accelerated transformation of domestic pharmaceutical companies towards evidence-driven marketing models, which has boosted the demand for precise omnichannel marketing solutions [1]
梅斯健康(02415)股东将股票由Merrill Lynch Far East Limited...